Axsome Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Axsome Therapeutics, Inc. on July 25, 2019. The filing details the entry into a material definitive agreement, specifically the First Amendment to a Loan and Security Agreement originally dated March 5, 2019, with Silicon Valley Bank (SVB) and WestRiver Innovation Lending Fund VIII, L.P.
Key Financial Metrics and Debt Structure
The filing focuses on debt restructuring rather than operational financial performance metrics such as revenue or cash flow, which are not provided in this document.
- Existing Debt: The Company has an outstanding Term A Loan Advance of $20,000,000.
- Potential Additional Debt: An unfunded Term B Loan Advance of $4,000,000 remains available.
- Interest Rate: Floating rate equal to the greater of 7.50% or 2.0% above the prime rate.
- Maturity Date: February 1, 2023.
- Final Payment Fee: Increased from 6.0% to 6.30% of the original principal amount.
- Prepayment Fees: 3.0% (within 1 year), 2.0% (years 1-2), or 1.0% (after year 2) of the prepaid amount.
Material Changes Versus Prior Period
The First Amendment introduces several material changes to the original Loan Agreement:
- Payment Extension: The interest-only monthly payment period was extended to 18 months, with the option to extend to 24 months upon funding of the Term B Loan Advance.
- Drawdown Extension: The deadline to draw down the $4,000,000 Term B Loan Advance was extended to December 31, 2019.
- Repayment Schedule: Principal repayment will occur in equal monthly installments over 30 months (or 24 months if the Milestone Event occurs) following the interest-only period.
- Warrant Adjustment: New warrants (July 2019 Warrants) were issued to replace the portion of warrants related to the Term B Loan Advance. The exercise price for these new warrants was increased from $8.10 to $25.71 per share for 5,750 shares per holder.
Guidance, Outlook, and Contingencies
The ability to access the additional $4,000,000 Term B Loan Advance is contingent upon a specific "Milestone Event."
- Milestone Event Requirement: The Company must achieve positive data from its Phase 2 clinical trial for AXS-12 prior to or on December 31, 2019, sufficient to submit a Phase 3 protocol to the FDA.
- Regulatory Condition: The Company must not receive any objections from the FDA within thirty days after the submission of the Phase 3 protocol.
- Warrant Exercisability: The July 2019 Warrants become exercisable only upon the funding of the Term B Loan Advance.
Key Facts for Investor Verification
- Verify the status of the Phase 2 clinical trial for AXS-12 to assess the likelihood of meeting the December 31, 2019 Milestone Event.
- Confirm the current status of the $4,000,000 Term B Loan Advance drawdown window.
- Review the impact of the increased warrant exercise price ($25.71) on potential future dilution compared to the original terms ($8.10).
- Monitor the Company's cash burn rate relative to the extended interest-only period to ensure liquidity sufficiency until the Milestone Event or maturity.